****New release Feb 2012***

MarketVIEW: Enterovirus-71 vaccines (CAT: VAMV032)

Product Name	:	**MarketVIEW:** *Enterovirus-71* vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 2 forecast models
Therapeutic Area	:	Novel pediatric/endemic vaccines
Publication date	:	February 2012
Catalogue No	:	VAMV032

Background

Enterovirus-71 (EV-71), a small member of the *picornaviridae* virus family, is a major causative agent of "hand foot and mouth" HFMD disease in South East Asia. In some countries EV-71 related HFMD outbreaks appear to be increasing in magnitude and frequency and are responsible for significant childhood mortality (905 deaths in China 2010) (*est* CFR 0.03%). Like Japanese encephalitis (JEV), an inactivated EV-71 vaccine has high likelihood of region specific national adoption in the SE Asia. Four such vaccines appear to be in late stage clinical trials in China with the first launch expected 2014.

This **MarketVIEW**[1] product is a comprehensive commercial opportunity assessment which forecasts the potential of EV-71 vaccines to 2030 in the SE Asia region. The product examines different scenarios of sucessive country based vaccine deployment in the <1 yrs and 1-5 yrs age groups. Detailed coverage of latest EV-71 epidemiology (outbreaks) is included, also a focus on development history/approaches to date and coverage of latest cost effectiveness issues. Expected revenues per competitor (public) sector are included for the late stage Phase III programs operated by Sinovac and China National Biotech Group (Beijing Vigoo Biological Co Ltd). This product is an ideal starting point for any manufacturer wishing to assess this emerging market in the SE Asia region.

[1] This product supercedes the previous **VacZine Analytics** publication **DiseaseINFOPACK**: Enterovirus-71 (CAT No:VADIP014),published August 2009

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Enterovirus-71 disease epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of pediatric/endemic vaccines has also been utilised. ***See Bibliography for exact sources**.

PRODUCT CONTENTS:

Published February 2012 (CAT No: VAMV032)

****This product is composed of three models and an Executive presentation

Contents – Executive presentation (MS PowerPoint based)

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

Continued……

PAGES: ~90 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)

Note: two models are included with differing vaccine price scenarios

Continued……

Country 5 – <1 yrs + 1-5 yrs
HI SCENARIO
Public + private
Country 4 – <1 yrs + 1-5 yrs
Country 5 – <1 yrs + 1-5 yrs
Populations =>>
Birth cohorts
Epidemiology =>>
% pub/priv
% Urban population
Total populations
Back page

Worksheets = 35 per model

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD **$9995.00**/ GBP **£6445.00**[#] (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
 # indicative only rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY:

1. WPRO Hand, Foot and Mouth Disease Situation Update, 12 January 2012. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012
2. Chang ZR et al. [Epidemiological features of hand, foot and mouth disease in China, 2008 - 2009]. Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Jul;32(7):676-80. [Article in Chinese]
3. Wang Y et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011 Nov;22(6):781-92.
4. Chinese Centre for Disease Control and Prevention and Office of the World Health Organization in China. Report on the Hand, foot, and mouth disease outbreak in Fuyang City, Anhui Province and prevention and control in China, May 2008. Available at: http://www.wpro.who.int/. Accessed: January 2012.
5. Zeng M et al. Epidemiology of hand, foot, and mouth disease in children in Shanghai 2007-2010. Epidemiol Infect. 2011 Aug 31:1-9.
6. Xu W et al. Hand, Foot and Mouth Disease in Yunnan Province, China, 2008-2010. Asia Pac J Public Health. 2011 Dec 23.
7. Chinese Center for Disease Control. May 2011. [In Chinese] Available at: http://www.yncdc.cn/UploadFile/files/20110527112598.ppt. Accessed: January 2012.
8. Chinese Centre for Disease Control and Prevention and Office of the World Health Organization in China. Report on the Hand, foot, and mouth disease outbreak in Fuyang City, Anhui Province and prevention and control in China, May 2008. Available at: http://www.wpro.who.int/. Accessed: January 2012.
9. Taiwan CDC. As enterovirus epidemic yet to abate and Taiwan CDC announces two new cases of enterovirus 71 infection with severe complications. Available at: http://www.cdc.gov.tw. Accessed: January 2012
10. Enterovirus Infection with Severe Complications in Taiwan. Available at: http://www.cdc.gov.tw/. Accessed: January 2012
11. Thai Department of Disease Control, Ministry of Public Health. National Disease Surveillance (report 506). Available at: http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=71. Accessed: January 2012.
12. Chatproedprai S et al. Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008-2009. Jpn J Infect Dis. 2010 Jul;63(4):229-33.
13. Puenpa J et al. Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011. Arch Virol. 2011 Nov;156(11):2007-13.
14. WPRO Hand, Foot and Mouth Disease Situation Update. 12 January 2012. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012.
15. Associated Press . Hand, foot, mouth disease kills 156 in Vietnam. 16 Dec 2011. Available at: http://news.yahoo.com/hand-foot-mouth-disease-kills-156-vietnam-060229890.html. Accessed: January 2012.
16. WPRO Hand, Foot and Mouth Disease Situation Update, 25 October 2011. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012.
17. WPRO Hand, Foot and Mouth Disease Situation Update, 4 Aug 2011. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012.
18. Chua KB et al. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011 Aug;26(4):221-8.
19. Chan, YF et al. Enterovirus 71 in Malaysia: A decade later. Neurology Asia 2011; 16(1) : 1 – 15
20. Ministry of Health, Malaysia. Health Facts 2009 /2010. Available from http://www.moh.gov.my/v/stats_si. Accessed January 2012.
21. WPRO Hand, Foot and Mouth Disease Situation Update, 29 Sep 2011. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012.
22. Ryu WS et al. Clinical and etiological characteristics of enterovirus 71-related diseases during a recent 2-year period in Korea. J Clin Microbiol. 2010 Jul;48(7):2490-4
23. Infectious Disease Surveillance Center. Annual Surveillance Data (page 2: Sentinel-Reporting Diseases). Available at: http://idsc.nih.go.jp/idwr/ydata/report-Eb.html. Accessed: January 2012.
24. Infectious Disease Surveillance Center. Digest No. 28 - July 17, July 11, 2011. [In Japanese]. Available at: http://idsc.nih.go.jp/idwr/douko/2011d/28douko.html. Accessed January 2012.
25. Hand-Foot-Mouth Disease Trend Graph (Weekly Report). Available at: http://idsc.nih.go.jp/idwr/kanja/weeklygraph/06HFMD-e.html. Accessed January 2012.
26. Infectious Disease Surveillance Center. Digest No. 36. - September 11, September 05, 2011. [In Japanese]. Available at: http://idsc.nih.go.jp/idwr/douko/2011d/36douko.html. Accessed January 2012.
27. Infectious Disease Surveillance Center. Aseptic meningitis pathogens, 2008-2012. Available at: http://idsc.nih.go.jp/. . Accessed January 2012.
28.

29. Fujimoto T et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46(9):621-7.
30. Weekly Infectious Disease Bulletin VOL. 8 NO.52 2011. Available at: http://www.moh.gov.sg. Accessed: January 2012.
31. Communicable Diseases Surveillance in Singapore 2010. 01 Nov 2011. Available at: http://www.moh.gov.sg. Accessed: January 2012.
32. WPRO Hand, Foot and Mouth Disease Situation Update. 25 January 2012. Available at: http://www.wpro.who.int/health_topics/hfmd/. Accessed: January 2012.
33. Khetsuriani N et al. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ. 2006 Sep 15;55(8):1-20.
34. Fowlkes AL et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis. 2008 Dec 1;198(11):1685-91.
35. Pérez-Vélez CM et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007 Oct 15;45(8):950-7
36. van der Sanden S et al. Epidemiology of Enterovirus 71 in the Netherlands, 1963-2008. J Clin Microbiol. 2009 Jul 22.
37. Huemer HP et al. Isolating Asian enterovirus 71 subgenogroup C4 in two Austrian clinical samples from 2004. Euro Surveill. 2008;13(28):pii=18922
38. Schuffenecker I et al. Epidemiology of human enterovirus 71 infections in France, 2000-2009. J Clin Virol. 2011 Jan;50(1):50-6.
39. Vallet S et al. Fatal case of enterovirus 71 infection, France, 2007. Emerg Infect Dis. 2009 Nov;15(11):1837-40
40. Badran SA et al. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis. 2011 Aug;43(8):642-8
41. Sasidharan CK et al. Hand-foot-and-mouth disease in Calicut. Indian J Pediatr. 2005 Jan;72(1):17-21.
42. Patil PR et al. Circulation of multiple enterovirus serotypes causing Hand, Foot and Mouth Disease in India. J Med Microbiol. 2011 Nov 3.
43. Beig FK et al. Etiology and clinico-epidemiological profile of acute viral encephalitis in children of western Uttar Pradesh, India. Int J Infect Dis. 2010 Feb;14(2):e141-6.
44. Luchs A et al. Evaluation of enterovirus 71 immune status in São Paulo state, Brazil. Rev Inst Med Trop Sao Paulo. 2010 Dec;52(6):339-41.
45. Chang LY et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007 Mar 22;356(12):1226-34.
46. Zhang D., et al. Enterovirus-71 vaccine: close but still far. Int J Inf Dis (2010) e739-e743
47. Huang ML et al. Enterovirus-71 vaccine. When will it be available? (2011); 110(7):425-427
48. Lee BY et al. Forecasting the economic value of an Enterovirus-71 (EV71) vaccine. Vaccine 28 (2010) 7731-7736
49. Liang Z et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 29 (2011) 9668-9674
50. US Census Bureau. International Database. Updated December 2010. Available at: http://www.census.gov/ipc/www/idb/. Accessed April 2011
51. The World Bank. Country and Lending Groups. Available at: http://data.worldbank.org/about/country-classifications/country-and-lending-groups. Accessed April 2011
52. VacZine Analytics. MarketVIEW: Japanese encephalitis vaccines (CAT No: VAMV012), published January 2012
53. National Vaccine Program Office (NVPO). The National Vaccine Advisory Committee. The Needs and Recommendations of the United States Poliovirus Stockpile. Available at: http://www.hhs.gov/nvpo/nvac/reports.html. Accessed February 2012
54. Lee BY., et al. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 28 (2010) 7731–7736
55. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, et al. Neutralizing antibody provided protection against Enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000;7:523–8
56. Wu CN et al. Protection against lethal Enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001;20:895–904.
57. Chang LY et al. Risk factors of Enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002;109:e88.
58. Ho M et al. An epidemic of Enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341:929–35.
59. Chang JY et al. Selection and Characterization of vaccine strain for Enterovirus-71 development. Vaccine 30 (2012) 703-11
60. Bek EJ., at al. Formalin-inactivated vaccine provokes cross protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29 (2011) 4829-4838
61. Huang SW et al. Re-emergence of enterovirus-71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 2009; 47: 3653-62

62. Wang JR et al. Change of major genotype of enterovirus 71 in outbreaks of HFMD in Taiwan between 1998-200. J Clin Micro 2002;40 (Jan 1):10-5
63. Chan YF., et al. Redesignation of Enterovirus-71 genotypes. International Journal of Infectious Diseases Volume 12, Supplement 1 , Page e303, December 2008
64. Fujimoto T et al. Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6, Japan, 2011. Vol 18, No 2. Feb 2012
65. Chen SP et al. Comparison of Clinical Features Between Coxsackievirus A2 and Enterovirus 71 During the Enterovirus Outbreak in Taiwan, 2008: A Children's Hospital Experience . J Microbial Immunol Infect 2010; 43(2):99-104
66. Zhu Z et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virology Journal 2010, 7:300
67. Melnick J. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields BN KD, Howley PM, eds: Fields Virology. Philadelphia: Lippincott-Raven Publishers, 1996:655-705.
68. Made-in-Malaysia HFMD vaccine. Available at: http://www.asiaone.com/Health/News/Story/A1Story20110605-282438.html. Accessed: January 2012.
69. Wu Z et al. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J Virol Methods. 2009 Aug;159(2):233-8
70. Chen TC et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009 Jul;53(7):2740-7.
71. Li ZH et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008 Mar 15;197(6):854-7.
72. Immuron Products and Pipeline. Available at: http://www.immuron.com/. Accessed: August 2009

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.

5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within **thirty days** of the invoice date.

7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com